Bio-Path Holdings
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 10
- Market Cap
- -
- Introduction
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
- Interventions
- Drug: BP1002; Liposomal Bcl-2 Antisense OligodeoxynucleotideDrug: Decitabine (in combination with BP1002)
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05190471
- Locations
- 🇺🇸
Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Scripps Green Hospital, La Jolla, California, United States
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Conditions
- Solid Tumor, AdultCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsEndometrial CancerPeritoneal CancerSolid Tumor
- Interventions
- Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04196257
- Locations
- 🇺🇸
Holy Cross Hospital, Silver Spring, Maryland, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- Conditions
- Waldenstrom MacroglobulinemiaChronic Lymphocytic Leukemia (CLL)Follicular LymphomaMantle Cell LymphomaCutaneous T-cell Lymphoma (CTCL)Small Lymphocytic Lymphoma (SLL)Marginal Zone LymphomaPeripheral T-cell Lymphoma (PTCL)Hodgkin LymphomaDLBCL
- Interventions
- Drug: L-Bcl-2 antisense oligonucleotide
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04072458
- Locations
- 🇺🇸
Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸New York Medical College / Westchester Medical Center, Valhalla, New York, United States
🇺🇸Sarah Cannon Research Institute/Tennesee Oncology, Nashville, Tennessee, United States
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelogenous Leukemia, Ph1-Positive
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Registration Number
- NCT02923986
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: BP1001 plus decitabineDrug: BP1001 in combination with Ventoclax plus decitabine
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT02781883
- Locations
- 🇺🇸
New Jersey Hematology Oncology Associates, Brick, New Jersey, United States
🇺🇸Baylor Scott & White Research Institute, Temple, Texas, United States
🇺🇸Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
- Conditions
- Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaPh1 Positive CMLMyelodysplastic Syndrome
- Interventions
- Drug: BP1001Drug: BP1001 in combination with LDAC
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01159028
- Locations
- 🇺🇸
M. D. Anderson Cancer Center, Houston, Texas, United States